Handelsbanken Fonder Ab Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Handelsbanken Fonder Ab

$23 Billion
Q2 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 27, 2022	SELL	$144.95 - $152.29 $8.12 Million - $8.53 Million	-56,000 Reduced 86.69%	8,600 $1.3 Million
Q2 2022 Aug 03, 2022	SELL	$83.14 - $145.99 $17.8 Million - $31.2 Million	-214,000 Reduced 76.81%	64,600 $9.41 Million
Q1 2022 May 11, 2022	SELL	$110.08 - $142.92 $935,680 - $1.21 Million	-8,500 Reduced 2.96%	278,600 $33 Million
Q4 2021 Feb 08, 2022	BUY	$99.73 - $148.48 $947,435 - $1.41 Million	9,500 Added 3.42%	287,100 $39.6 Million
Q3 2021 Nov 10, 2021	SELL	$98.85 - $138.91 $1.48 Million - $2.08 Million	-15,000 Reduced 5.13%	277,600 $38.6 Million
Q2 2021 Aug 03, 2021	BUY	$65.78 - $105.02 $1.64 Million - $2.63 Million	25,000 Added 9.34%	292,600 $28.4 Million
Q1 2021 Apr 29, 2021	BUY	$64.07 - $91.75 $2.24 Million - $3.21 Million	35,000 Added 15.05%	267,600 $18.3 Million
Q4 2020 Feb 11, 2021	SELL	$65.07 - $98.24 $2.4 Million - $3.63 Million	-36,900 Reduced 13.69%	232,600 $19.9 Million
Q3 2020 Nov 13, 2020	BUY	$59.04 - $77.95 $1.49 Million - $1.96 Million	25,200 Added 10.32%	269,500 $17.5 Million
Q2 2020 Aug 13, 2020	SELL	$29.01 - $74.23 $78,327 - $200,421	-2,700 Reduced 1.09%	244,300 $17.9 Million
Q1 2020 May 14, 2020	SELL	$27.51 - $57.29 $275,100 - $572,900	-10,000 Reduced 3.89%	247,000 $8.41 Million
Q4 2019 Feb 14, 2020	BUY	$40.86 - $57.65 $1.02 Million - $1.44 Million	25,000 Added 10.78%	257,000 $14 Million
Q3 2019 Oct 31, 2019	BUY	$37.38 - $49.47 $2.99 Million - $3.96 Million	80,000 Added 52.63%	232,000 $9.68 Million
Q2 2019 Jul 12, 2019	BUY	$39.79 - $67.01 $6.05 Million - $10.2 Million	152,000 New	152,000 $6.66 Million

Others Institutions Holding BHVN

# of Institutions

Shares Held

785K

Call Options Held

Put Options Held

View Full List

About Biohaven Pharmaceutical Holding Co Ltd.

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

More about BHVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.

Account